Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

Gene expression associated with lentiviral expression of PRAME in normal hematopoietic progenitors.

ABSTRACT: To identify gene expression that distinguishes hematopoietic cells that express PRAME from those that do not, normal CD34+ cells with forced PRAME expression were compared to cells without PRAME expression in culture over time (days 4, 7, 14) using Affymetrix HU-133A microarrays Normal CD34+ progenitor cells not expressing PRAME were transduced with either PRAME cDNA (no 3' utr) or a corresponding empty vector control by lentiviral vector infection. Two replicates were performed for each condition (PRAME and control) at three experimental time points (days 4, 7, and 14 in culture). A single-stranded linear amplification protocol was used to process total RNA (one microgram) for the microarrays. This protocols is described in detail in PMID 14706461.

ORGANISM(S): Homo sapiens

SUBMITTER: Vivian Oehler 

PROVIDER: E-GEOD-17100 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

Json Xml
altmetric image

Publications

The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells.

Oehler Vivian G VG   Guthrie Katherine A KA   Cummings Carrie L CL   Sabo Kathleen K   Wood Brent L BL   Gooley Ted T   Yang Taimei T   Epping Mirjam T MT   Shou Yaping Y   Pogosova-Agadjanyan Era E   Ladne Paula P   Stirewalt Derek L DL   Abkowitz Janis L JL   Radich Jerald P JP  

Blood 20090722 15

The preferentially expressed antigen in melanoma (PRAME) is expressed in several hematologic malignancies, but either is not expressed or is expressed at only low levels in normal hematopoietic cells, making it a target for cancer therapy. PRAME is a tumor-associated antigen and has been described as a corepressor of retinoic acid signaling in solid tumor cells, but its function in hematopoietic cells is unknown. PRAME mRNA expression increased with chronic myeloid leukemia (CML) disease progres  ...[more]

Similar Datasets

Transcriptomics The Histone Methyltransferases MLL1 and DOT1L Cooperate with Meningioma-1 to Induce AML
2016-01-12 | E-GEOD-76750 | biostudies-arrayexpress
Transcriptomics Expression data from CD34+/CD71- cells following knockdown of HSPA9
2016-02-23 | E-GEOD-78164 | biostudies-arrayexpress
Transcriptomics Gene expression profiles in mouse common myeloid progenitor (CMP) and leukemia cells expressing full-length MN1 or truncated versions of MN1 protein
2013-06-13 | E-GEOD-38767 | biostudies-arrayexpress
Transcriptomics Amplicon-seq of an enhancer region targeted by CRISPR to assess the mutations introduced by different sgRNA guides
2021-07-26 | E-MTAB-9945 | biostudies-arrayexpress
Genomics Cut&Run-seq of MUTZ3 cells to investigate changes in a translocated enhancer following CRISPR treatment
2021-07-26 | E-MTAB-9946 | biostudies-arrayexpress
Transcriptomics ATAC-seq of MUTZ3 cells in experiments to investigate EVI1 regulation
2021-07-26 | E-MTAB-9949 | biostudies-arrayexpress
Transcriptomics MEIS2 is a novel oncogenic partner in AML1-ETO positive AML [RNA-Seq mouse]
2016-07-04 | E-GEOD-81329 | biostudies-arrayexpress
Genomics Genome wide mapping of histone 3 lysine 79 mono, di and trimethylation and histone 3 lysine 27 trimethylation in LSKs, GMPs and retroviral MLL-AF9 driven murine leukemias
2014-09-08 | E-GEOD-55038 | biostudies-arrayexpress
Transcriptomics Determination of HOXA1 and HOXA9 target genes with inducible HOX constructs
2012-11-02 | E-MEXP-3648 | biostudies-arrayexpress
Transcriptomics Intrinsic Protection From Leukemic Transformation at The Level of Hematopoietic Stem Cells
2015-01-01 | E-GEOD-62734 | biostudies-arrayexpress